BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 22150305)

  • 41. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
    Crispino JD
    Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.
    Taub JW; Matherly LH; Stout ML; Buck SA; Gurney JG; Ravindranath Y
    Blood; 1996 Apr; 87(8):3395-403. PubMed ID: 8605357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
    Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
    Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Natural history of GATA1 mutations in Down syndrome.
    Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
    Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
    Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
    Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of a clone-specific GATA1 mutation to monitor treatment response and involvement of a monozygotic twin in myeloid leukemia of Down syndrome.
    Ali S; Ashraf K; Chen J; Hitzler JK
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28074551
    [No Abstract]   [Full Text] [Related]  

  • 49. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.
    Hitzler JK; Cheung J; Li Y; Scherer SW; Zipursky A
    Blood; 2003 Jun; 101(11):4301-4. PubMed ID: 12586620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21.
    Tigay JH
    J Pediatr Oncol Nurs; 2009; 26(6):362-8. PubMed ID: 20032297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
    Labuhn M; Perkins K; Matzk S; Varghese L; Garnett C; Papaemmanuil E; Metzner M; Kennedy A; Amstislavskiy V; Risch T; Bhayadia R; Samulowski D; Hernandez DC; Stoilova B; Iotchkova V; Oppermann U; Scheer C; Yoshida K; Schwarzer A; Taub JW; Crispino JD; Weiss MJ; Hayashi Y; Taga T; Ito E; Ogawa S; Reinhardt D; Yaspo ML; Campbell PJ; Roberts I; Constantinescu SN; Vyas P; Heckl D; Klusmann JH
    Cancer Cell; 2019 Aug; 36(2):123-138.e10. PubMed ID: 31303423
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
    Watanabe K
    Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
    Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
    Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
    PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term outcome for Down syndrome patients with hematopoietic disorders.
    Li MJ; Lee NC; Yang YL; Yen HJ; Chang HH; Chien YH; Lu MY; Jou ST; Lin KH; Hwu WL; Lin DT
    J Formos Med Assoc; 2016 Feb; 115(2):94-9. PubMed ID: 26234152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
    Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
    Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
    Satgé D
    Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome.
    Alford KA; Slender A; Vanes L; Li Z; Fisher EM; Nizetic D; Orkin SH; Roberts I; Tybulewicz VL
    Blood; 2010 Apr; 115(14):2928-37. PubMed ID: 20154221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.
    Groet J; McElwaine S; Spinelli M; Rinaldi A; Burtscher I; Mulligan C; Mensah A; Cavani S; Dagna-Bricarelli F; Basso G; Cotter FE; Nizetic D
    Lancet; 2003 May; 361(9369):1617-20. PubMed ID: 12747884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
    Kanezaki R; Toki T; Terui K; Xu G; Wang R; Shimada A; Hama A; Kanegane H; Kawakami K; Endo M; Hasegawa D; Kogawa K; Adachi S; Ikeda Y; Iwamoto S; Taga T; Kosaka Y; Kojima S; Hayashi Y; Ito E
    Blood; 2010 Nov; 116(22):4631-8. PubMed ID: 20729467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.